Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Loss Of Endothelial Cell-Specific Autophagy-Related Protein 7 Exacerbates Doxorubicin-Induced Cardiotoxicity, Albert Z. Luu, Vincent Z. Luu, Biswajit Chowdhury, Andrew Kosmopoulos, Yi Pan, Mohammed Al-Omran, Adrian Quan, Hwee Teoh
Loss Of Endothelial Cell-Specific Autophagy-Related Protein 7 Exacerbates Doxorubicin-Induced Cardiotoxicity, Albert Z. Luu, Vincent Z. Luu, Biswajit Chowdhury, Andrew Kosmopoulos, Yi Pan, Mohammed Al-Omran, Adrian Quan, Hwee Teoh
Paediatrics Publications
Doxorubicin (DOX) is an effective, broad-spectrum antineoplastic agent with serious cardiotoxic side effects, which may lead to the development of heart failure. Current strategies to diagnose, prevent, and treat DOX-induced cardiotoxicity (DIC) are inadequate. Recent evidence has linked the dysregulation and destruction of the vascular endothelium to the development of DIC. Autophagy is a conserved pro-survival mechanism that recycles and removes damaged sub-cellular components. Autophagy-related protein 7 (ATG7) catalyzes autophagosome formation, a critical step in autophagy. In this study, we used endothelial cell-specific Atg7 knockout (EC-Atg7−/−) mice to characterize the role of endothelial cell-specific autophagy in DIC. DOX-treated EC-Atg7−/− mice …
Role Of Endothelium In Doxorubicin-Induced Cardiomyopathy, Albert Z. Luu, Biswajit Chowdhury, Mohammed Al-Omran, Hwee Teoh, David A. Hess, Subodh Verma
Role Of Endothelium In Doxorubicin-Induced Cardiomyopathy, Albert Z. Luu, Biswajit Chowdhury, Mohammed Al-Omran, Hwee Teoh, David A. Hess, Subodh Verma
Paediatrics Publications
The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.